- Kon Yew Kwek, BM BCh, DPhil, appointed Chief Medical Officer
- Lisa Ooi, PhD, appointed Chief Operating Officer
SAN FRANCISCO and SINGAPORE, July 29, 2024 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced the internal appointments of Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.
Dr. Kwek is promoted to Chief Medical Officer, from Senior Vice President of Clinical Development. Dr. Kwek joined the company in 2022 and brings two decades of experience from Akeso Biopharma, Eli Lilly and IQVIA and clinical practice. Dr. Kwek will lead the company’s clinical development from Singapore.
“Our clinical-stage assets, HMBD-001 and HMBD-002, are in clinical trials in the U.S., Australia, and Singapore. And now, we are accelerating the development of these therapies by expanding our trial sites to more countries and focusing on selected tumor types, which we believe may benefit from these therapies. I look forward to the next milestones in our clinical programs and progressing more of our pre-clinical pipeline to the clinic,” said Dr. Kwek.
Dr. Ooi is promoted to Chief Operating Officer, from Senior Vice President of Strategy. Dr. Ooi joined the company in 2022 and brings two decades of experience from Singapore’s government agencies and biopharma industry, including: Economic Development Board, Agency for Science, Technology and Research (A*STAR), ASLAN Pharmaceuticals and Bayer.
“I am delighted to lead the team’s strategy towards its next phase of growth, building upon our strong scientific capabilities and commitment to deeply understanding tumor biology. With our proprietary antibody and dual-payload ADC platform technologies, I look forward to what we will achieve in the coming year,” said Dr. Ooi.
About Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases. To address key challenges with current antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is building a pipeline of next-generation ADCs using its proprietary antibody discovery and linker/payload platforms. The company has a pipeline of ADCs in preclinical development and other novel biologics including monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Phase I and a recently out-licensed ADC (HMBD-501) that will enter the clinic this year. The Hummingbird Bioscience approach combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. The company harnesses this integrated approach across target identification and patient selection, enabling the team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
Hummingbird Bioscience Media Contact:
Crystal Ho
c.ho@hummingbirdbio.com
media@hummingbirdbio.com
+65 6979 5580
Hummingbird Bioscience Investor Contact:
investors@hummingbirdbio.com
-
Hummingbird Bioscience Announces Key Leadership AppointmentsKon Yew Kwek, BM BCh, DPhil, appointed Chief Medical Officer Lisa Ooi, PhD, appointed Chief Operating Officer SAN FRANCISCO and SINGAPORE, Ju2024-07-29
-
数据驱动的智能媒体新时代随着信息技术的不断发展,媒体平台成为人们获取信息、传播观点、进行社交交流的重要渠道之一。然而,过程中如果缺少了数据分析的支持,容易出现运营不精准、管理难跟进2024-07-29
-
张家辉获马来西亚国际电影节大奖 新作《赎梦》成闭幕电影两届金像影帝张家辉,其执导及主演的新作《赎梦》成为第7届马来西亚国际电影节(MIFFest)的闭幕电影,演而优则导的张家辉获大会颁发本届「卓越电影成就奖」。前日(7月272024-07-29
-
《你比星光美丽》今日收官 宫小喧演绎中国式母亲 真诚情感打动人心由陈畅执导,杨千紫担任编剧,谭松韵、许凯等主演,宫小喧出演的职场爱情剧《你比星光美丽》已于今日收官。该剧讲述了北漂女孩纪星不甘于压抑内卷的职场生活,辞职走上艰2024-07-29
-
"WhatsApp引流新纪元 揭秘WS批量群发的5种技术路径教程想要通过WhatsApp高效引流,却不知从何下手?我们精心整理了WS批量群发的5种技术路径教程,涵盖从基础设置到高级优化的全方位指南。无论您是营销新手还是资深玩家,都能2024-07-29